Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 9 recruiting now early-phase tilt

Substance Abuse: early-phase trial registry

9 of 59 indexed Substance Abuse trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #241 of 28,707 conditions by registered trial count.

59 US clinical trials · 9 currently recruiting · #241 of 28,707 conditions by registered trial count

Substance Abuse: 59 US clinical trials tracked, 9 recruiting.

Substance Abuse is the subject of 59 registered US clinical trials on ClinicalTrials.gov, 9 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 14 in Phase 1-2 (earlier-stage). The most active sponsor is Yale University, running 6 of these trials.

Enrollment posture brief

Registry condition substance-abuse

OPEN 9 | RECR 15% | LATE 2 | EARLY 14 | RANK #241 | SPON 6

Nearest open-share peer: Arthroplasty, Replacement, Knee (15% recruiting · 13 trials)

Anatomic Stage IV Breast Can70%Hearing Loss50%HER2-positive Breast Cancer47.5%Substance Abuse (this)15%Opioid-Related Disorders13.6%
Open-enrollment share among volume-matched conditions near Substance Abuse

Substance Abuse lists 9 open slots (15% of 59 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Substance Abuse on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Substance Abuse is recruiting below its size-band peers.

    9 of 59 indexed trials (15.3%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Substance Abuse trials is spread across many organizations.

    Yale University accounts for 6 of 59 trials (10.2%). 38 distinct sponsors appear on at least one study for this condition label.

  3. Typical Substance Abuse enrolment sits around 144 participants.

    Median target enrolment is 144 among the 59 trials that report a genuine target (sentinel values excluded). 25 of those (42.4%) plan for fewer than 100 participants.

  4. Substance Abuse research is mostly interventional.

    53 interventional and 6 observational studies make up this index (89.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 16Phase 28Phase 31Phase 41

Open and recent trials

59 total, page 1 of 2

RECRUITING 7,500 participants

Substance Abuse Pre-Treatment Screening Study

The University of Texas Health Science Center, Houston

NCT00439049

RECRUITING NA 400 participants

SER Familia: A Family-Based Intervention Addressing Syndemic Conditions Among Latino Immigrant Families

Duke University

NCT06627764

RECRUITING NA 341 participants

Data2Action Oregon Project: Supporting Data-driven Decision-Making for Substance Use Services, Policy, and Overdose Prevention

Chestnut Health Systems

NCT06852170

RECRUITING NA 300 participants

Testing Strategies to Improve Substance Misuse Prevention Research Use in State Policy Contexts

Penn State University

NCT06856148

RECRUITING NA 200 participants

Harm Reduction Services

NYU Langone Health

NCT05776316

RECRUITING NA 144 participants

The STop UNhealthy Substance Use Now Trial

Ohio State University

NCT06524232

RECRUITING NA 124 participants

The Trans-Led Care Study

Illinois Institute of Technology

NCT06880705

RECRUITING NA 80 participants

Functional Connectivity Alterations in Suicidal Patients Among Opioid Users

Baylor College of Medicine

NCT05489042

RECRUITING NA 42 participants

Testing ALERT With GTO in Middle Schools

RAND

NCT05219422

ACTIVE NOT RECRUITING NA 52,323 participants

The Community Youth Development Study: A Test of Communities That Care

University of Washington

NCT01088542

ACTIVE NOT RECRUITING NA 752 participants

Kentucky Outreach Service Kiosk (KyOSK): Reducing HIV, HCV, and Overdose Risk

April M Young

NCT05657106

ACTIVE NOT RECRUITING NA 600 participants

Addressing Risk Through Community Treatment for Infectious Disease and Opioid Use Disorder Now (ACTION) Among Justice-involved Populations

Yale University

NCT05286879

ACTIVE NOT RECRUITING NA 504 participants

Continuing Care Following Drug Abuse Treatment: Linkage With Primary Care

Kaiser Permanente

NCT01621711

ACTIVE NOT RECRUITING NA 14 participants

Nexalin Therapy as a Viable Adjunctive Treatment for Substance Use Disorders

University of Arizona

NCT03540745

ACTIVE NOT RECRUITING NA 10 participants

Breathwork-assisted Treatment for Cannabis Use Disorder

Elias Dakwar

NCT05219825

COMPLETED 113,123 participants

A Phased-Implementation Feasibility and Proof-of-Concept Study to Assess Incorporating the NIDA CTN Common Data Elements (CDEs) Into the Electronic Health Record (EHR) in Large Primary Care Settings ("CDE-EHR-PC" Study), Phase 3

NYU Langone Health

NCT02963948

COMPLETED NA 64,996 participants

Data-driven Identification for Substance Misuse

University of Wisconsin, Madison

NCT03833804

COMPLETED 53,132 participants

Physician Coaching to Reduce Opioid-related Harms

University of Wisconsin, Madison

NCT02433496

COMPLETED NA 3,358 participants

Integrated Care (iCare) at Mount Sinai to Improve Substance Use Diagnosis and Treatment Practices in HIV Clinic Settings

Icahn School of Medicine at Mount Sinai

NCT03092596

COMPLETED NA 843 participants

Personalized Health Assessment Related to Medications (Project PHARM)

University of Washington

NCT03037476

COMPLETED NA 612 participants

Fetal Alcohol Damage Prevention Study

Massachusetts General Hospital

NCT00696085

COMPLETED NA 518 participants

Master Mind Program Evaluation Study

Innovation Research & Training

NCT03212066

COMPLETED NA 507 participants

Web-delivery of Evidence-based, Psychosocial Treatment for Substance Use Disorders

New York State Psychiatric Institute

NCT01104805

COMPLETED Phase 2 376 participants

Enhancing Prevention Capacity With Developmental Assets and Getting to Outcomes

RAND

NCT00780338

COMPLETED NA 340 participants

Contingency Management for Smoking in Substance Abusers

Brown University

NCT00807742

COMPLETED Phase 2 328 participants

Building Outcomes With Observation-Based Supervision: An FFT Effectiveness Trial

Oregon Research Institute

NCT01614015

COMPLETED NA 310 participants

Teen Success Project

Chestnut Health Systems

NCT03015805

COMPLETED Phase 2 270 participants

Evaluation of Treatments for Homeless Youths

Ohio State University

NCT01143792

COMPLETED NA 266 participants

Family Listening Program: Multi-Tribal Implementation and Evaluation

University of New Mexi

NCT03142009

COMPLETED Phase 1 225 participants

Youth Substance Use Prevention/Reduction Through Science-based Drug Abuse Education

Boston Children's Hospital

NCT00612482

COMPLETED NA 191 participants

Family-Based Treatment for Parental Substance Abuse and Child Maltreatment

Medical University of South Carolina

NCT01656837

COMPLETED Phase 1 183 participants

Adolescent Involvement in Parental Substance Abuse Treatment

Ohio State University

NCT01576393

COMPLETED Phase 1 164 participants

Computer Based Training in Cognitive Behavioral Therapy Web-based

Yale University

NCT01442597

COMPLETED NA 164 participants

OPTIONS: A Patient-Centered HIV Prevention Decision Aid for PrEP Uptake for Women With Substance Use in Treatment Settings

Yale University

NCT03651453

COMPLETED NA 150 participants

An Evaluation of JUST Court in Yuma County, AZ

Pepperdine University

NCT02449057

COMPLETED Phase 1 140 participants

The Men's Domestic Abuse Check-Up Engages Adult Men Concerned About Their Abusive Behavior and Alcohol or Drug Use

University of Washington

NCT01621334

COMPLETED Phase 3 140 participants

Medication Treatment for Opioid Use Disorder in Expectant Mothers

T. John Winhusen, PhD

NCT03918850

COMPLETED NA 121 participants

Juvenile Offender HIV Prevention and Drug Abuse Services

University of Miami

NCT01922297

COMPLETED 97 participants

Medication Treatment for Opioid Use Disorder in Expectant Mothers: Conceptual Model Assessments Sub-study

T. John Winhusen, PhD

NCT03911466

COMPLETED NA 96 participants

CARESS: An Investigation of Effects of CARESS

Inova Health Care Services

NCT03758027

COMPLETED Phase 2 90 participants

Aripiprazole Treatment for Methamphetamine Dependence Among High-risk Individuals

San Francisco Department of Public Health

NCT00497055

COMPLETED NA 86 participants

To Reach Unrestricted Services for Transgender Women

University of Central Florida

NCT03877497

COMPLETED NA 84 participants

Substance Abuse Treatment for High Risk Chronic Pain Patients on Opioid Therapy

Brigham and Women's Hospital

NCT00988962

COMPLETED Phase 2 84 participants

Study of Medical Treatment for Methamphetamine Addiction

University of California, Los Angeles

NCT00833443

COMPLETED NA 83 participants

Computer-Assisted Brief Intervention

Brown University

NCT03107117

COMPLETED Phase 1 72 participants

Rivastigmine and Huperzine A as Treatments for Cocaine Dependence

Baylor College of Medicine

NCT01030692

COMPLETED 71 participants

Medication Treatment for Opioid Use Disorder in Expectant Mothers: Infant Neurodevelopmental Outcomes Sub-study

T. John Winhusen, PhD

NCT03911739

COMPLETED NA 70 participants

Atomoxetine for Attention Deficit Hyperactivity Disorder in Adolescents With Substance Use Disorder

Denver Health and Hospital Authority

NCT00399763

COMPLETED NA 63 participants

An Integrated Substance Abuse-Domestic Violence (SADV) Treatment Outcome Study

Yale University

NCT07140276

COMPLETED Phase 2 60 participants

Substance Treatment and HIV Testing and Referral System

Polaris Health Directions

NCT01488630

Page 1 of 2 Next →

Phase Distribution

PhaseTrial count
Phase 1 6
Phase 2 8
Phase 3 1
Phase 4 1

Named interventions

Most-linked intervention names on Substance Abuse records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
4 trials
Buprenorphine Sublingual Product Drug
3 trials
Buprenorphine Injection Drug
3 trials
Contingency Management Behavioral
3 trials
Standard Treatment As Usual (TAU) Behavioral
2 trials
drug prevention curriculum Other
1 trials
Services remain dispersed; i.e., not centralized to one-location or provider. Other
1 trials
Services will be provided at one site Other
1 trials

US sites by state

Facility locations filed on Substance Abuse trials. A trial with sites in several states counts in each.

Connecticut 10 trials
Massachusetts 8 trials
Washington 7 trials
Oregon 7 trials
Texas 6 trials
Florida 6 trials
California 6 trials
Pennsylvania 5 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Substance Abuse page

59 registered trials, 9 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 9 Substance Abuse trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Yale University sponsors the most Substance Abuse trials on record, review their full trial history before evaluating a specific study. See Yale University's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Substance Abuse condition card totals 59 registered trials; most-linked intervention Placebo; top US site state Connecticut. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.